130 related articles for article (PubMed ID: 26258670)
1. Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population.
McGlasson DL; Fritsma GA
Blood Coagul Fibrinolysis; 2016 Jan; 27(1):53-7. PubMed ID: 26258670
[TBL] [Abstract][Full Text] [Related]
2. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
3. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
[TBL] [Abstract][Full Text] [Related]
4. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG
Solbeck S; Jensen AS; Maschmann C; Stensballe J; Ostrowski SR; Johansson PI
Scand J Clin Lab Invest; 2018; 78(1-2):25-30. PubMed ID: 29304563
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring.
Poli S; Härtig F; Spencer C; Ebner M; Birschmann I; Kuhn J; Faix S; Ziemann U; Häring HU; Lehmann R; Peter A; Hörber S
Thromb Haemost; 2017 Dec; 117(12):2369-2375. PubMed ID: 29212124
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study.
de Fautereau-Vassel A; Mokhtarian A; Mangenot M; Krekounian O; Kousignian I; Delavenne X; Curis E; Gouin-Thibault I; Siguret V
Int J Lab Hematol; 2024 Feb; 46(1):120-127. PubMed ID: 37710085
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.
Jaffer IH; Chan N; Roberts R; Fredenburgh JC; Eikelboom JW; Weitz JI
J Thromb Haemost; 2017 Dec; 15(12):2377-2387. PubMed ID: 28976630
[TBL] [Abstract][Full Text] [Related]
8. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
[TBL] [Abstract][Full Text] [Related]
9. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
10. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
11. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
[TBL] [Abstract][Full Text] [Related]
12. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
13. Laboratory assessment of the anticoagulant activity of dabigatran.
Kyriakou E; Ikonomidis I; Stylos D; Bonovas S; Papadakis I; Nikolopoulos GK; Kokoris S; Kalantzis D; Economopoulou C; Kopterides P; Lekakis J; Tsantes AE
Clin Appl Thromb Hemost; 2015 Jul; 21(5):434-45. PubMed ID: 25525048
[TBL] [Abstract][Full Text] [Related]
14. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
15. Assessing the anticoagulant effect of dabigatran in children: an in vitro study.
Dietrich K; Stang L; van Ryn J; Mitchell LG
Thromb Res; 2015 Apr; 135(4):630-5. PubMed ID: 25715905
[TBL] [Abstract][Full Text] [Related]
16. Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register.
Cini M; Legnani C; Cosmi B; Testa S; Dellanoce C; Paoletti O; Marcucci R; Poli D; Paniccia R; Pengo V; Tripodi A; Palareti G;
Int J Lab Hematol; 2018 Apr; 40(2):229-236. PubMed ID: 29314632
[TBL] [Abstract][Full Text] [Related]
17. Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran.
Härtig F; Birschmann I; Peter A; Ebner M; Spencer C; Gramlich M; Richter H; Kuhn J; Lehmann R; Blumenstock G; Zuern CS; Ziemann U; Poli S
Thromb Haemost; 2021 Jun; 121(6):782-791. PubMed ID: 33469905
[TBL] [Abstract][Full Text] [Related]
18. Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests.
Solbeck S; Ostrowski SR; Stensballe J; Johansson PI
Int J Cardiol; 2016 Apr; 208():14-8. PubMed ID: 26826624
[TBL] [Abstract][Full Text] [Related]
19. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods.
Du S; Weiss C; Christina G; Krämer S; Wehling M; Krämer R; Harenberg J
Clin Chem Lab Med; 2015 Jul; 53(8):1237-47. PubMed ID: 25720084
[TBL] [Abstract][Full Text] [Related]
20. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits.
McGlasson DL; Fritsma GA
Semin Thromb Hemost; 2013 Apr; 39(3):315-9. PubMed ID: 23468380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
